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Evan Wuthrick, MD, is one of the Chief 
Residents in the Department of Radiation 
Oncology. He will finish his training here at 
Jefferson on June 30, 2011.
Dr. Wuthrick was selected to participate in 
two workshops sponsored by the American 
Association of Cancer Research/ American Society of Clinical Oncology. 
In July 2010 he attended the Molecular Biology in Clinical Oncology 
workshop held at the Given Institute of the University of Colorado in 
Aspen. It was an intensive, week-long educational opportunity on the 
latest developments in molecular biology relevant to clinical oncologists. 
New research on the molecular mechanisms that control cell growth 
has led to a rapid expansion in the understanding of the nature of 
cancer cells which has opened many potential avenues of translational 
cancer research. The goal will be to provide a thorough overview 
of the emerging role of molecular biology in clinical cancer care.
In August 2010 Dr. Wuthrick attended the American Society of 
Clinical Oncology/American Association of Cancer Researchers 
sponsored workshop entitled Methods in Clinical Cancer Research. 
The workshop was held in Vail, Colorado and focused on the design 
and conduct of clinical trials. Clinical trials completed in oncology 
provide definitive answers about the effectiveness of new approaches 
to cancer treatment or prevention. As part of the application for this 
workshop, Dr. Wuthrick submitted a detailed clinical trial proposal 
entitled, “Pilot Study to Reduce the Severity of Gastrointestinal 
Toxicity Using Concurrent Linaclotide with Chemoradiotherapy 
in Pancreatic Adenocarcinoma.” The concept for this proposed 
clinical trial stems from work done in the laboratory of Dr. Scott 
Waldman, Professor and Chair of the Department of Pharmacology 
and Experimental Therapeutics at Jefferson.
Basic Research Studies/Grants
• 17AAG abrogates repair of DSBs by HR in tumor cells at acidic 
pH but not at pH7.3
• Spatial Response of Locally Advanced Non-Small Cell Lung 
Tumors to Radiotherapy: A Secondary Analysis of ACRIN 
6668 / RTOG 0235 
• Prostate Cancer Foundation Young Investigator Awards
• RTOG Group Member Agreement  
 – Physicist Chair 
 – Vice Chair Translational Research Program
Clinical Research Studies/Grants
• RTOG #0848 : A Phase III Trial Evaluating Both Erlotinib 
and Chemoradiation as Adjuvant Treatment for Patients with 
Resected Head of Pancreas Adenocarcinoma
• RTOG #0815 : A Phase III Prospective Randomized Trial of 
Dose-Escalated Radiotherapy with or without Short-Term 
Androgen Deprivation Therapy for Patients with Intermediate-
Risk Prostate Cancer
• NIH: Phase I Study: Using EUCLIDIAN Robotic Assistance 
During Prostate Brachytherapy (NIH/NCI CA091763: CA107860)
• RTOG #0831/Cialis: A randomized, double-blinded, placebo-
controlled phase III trial to evaluate the effectiveness of 
a phosphodiesterase 5 inhibitor, tadalafil, in prevention of 
erectile dysfunction in patients treated with radiotherapy for 
prostate cancer
• Wyeth/Pfizer : A Pilot Study of Chemoradiotherapy Plus 
Temsirolimus (Torisel) for Advanced Head and Neck Cancer
• RTOG #0631: Phase II/III Study of Image-Guided Radiosurgery/
SBRT for Localized Spine Metastasis
• RTOG #0627: Phase II Trial of Dasatinib in Patients with 
Recurrent Glioblastoma Multiforme 
• NCCTG #N0577: Phase III Intergroup Study of Radiotherapy 
versus Temozolomide alone versus Radiotherapy with 
Concomitant and Adjuvant Temozolomide for Patients with 
1p/19q Codeleted Anaplastic Glioma
• RTOG #0539: Phase II Trial of Observation for Low-Risk 
Meningiomas and of Radiotherapy for Intermediate- and High-
Risk Meningiomas
• ECOG E3F05: Phase III Study of Radiation Therapy with 
or without Temozolomide for Symptomatic or Progressive 
Low-Grade Gliomas
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